First patients test new cancer drug in early safety study
NCT ID NCT02689505
Summary
This was an early safety study to test a new cancer drug called BI 836880 in people with advanced solid tumors. The main goal was to find the highest dose patients could tolerate without severe side effects. Researchers gave the drug weekly to 24 patients and closely monitored their health to determine a safe dose for future testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTR Georges-François Leclerc
Dijon, 21079, France
-
Hospital Vall d'Hebron
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.